Will Savings From Biosimilars Offset Increased Costs Related to Dose Escalation? A Comparison of Infliximab and Golimumab for Rheumatoid Arthritis
Arthritis Research & Therapy
doi 10.1186/s13075-019-2022-8
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Springer Science and Business Media LLC